期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
POM analysis and computational interactions of 8-hydroxydiospyrin inside active site of protein tyrosine phosphatase 1B
1
作者 SAUD BAWAZER ASGHAR KHAN +9 位作者 ABDUR RAUF TAIBI B EN HADDA YAHYA SAL-AWTHAN OMAR BAHATTAB UMER RASHID INAMULLAH KHAN MUHAMMAD A SIF NAWAZ MD SAHAB UDDIN OLATUNDE AHMED MOHAMMAD A LI SHARIATI 《BIOCELL》 SCIE 2021年第3期751-759,共9页
Proteintyrosine phosphatase 1B(PTP1B)inhibitionis consideredas a potentialtherapeuticfor the treatmentof cancer,type2 diabetes,andobesity.Inour presentwork,weinvestigatedtheanti-diabeticpotentialof8-hydroxydiospyrin(8... Proteintyrosine phosphatase 1B(PTP1B)inhibitionis consideredas a potentialtherapeuticfor the treatmentof cancer,type2 diabetes,andobesity.Inour presentwork,weinvestigatedtheanti-diabeticpotentialof8-hydroxydiospyrin(8-HDN)from D.lotus against the PTP1B enzyme.It showed significant inhibitory activity of PTP1B with an IC 50 value of 18.37±0.02μM.A detailed molecular docking study was carried out to analyze the binding orientation,binding energy,and mechanism of inhibition.A comparative investigation of 8-HDN in the catalytic,as well as the allosteric site of PTP1B,was performed.Binding energy data showed that compound 8-HDN is more selective for the allosteric site and hence avoids the problems associated with catalytic site inhibition.The inhibition mechanism of 8-HDN can be further investigated as an active lead compound against PTP1B by using in vitro and in vivo models. 展开更多
关键词 Diospyros lotus ROOTS 8-Hydroxydiospyrin Molecular docking Protein tyrosine phosphatase 1B
下载PDF
Link between COVID-19 vaccines and myocardial infarction
2
作者 Umema Zafar Hamna Zafar +1 位作者 Mian Saad Ahmed Madiha Khattak 《World Journal of Clinical Cases》 SCIE 2022年第28期10109-10119,共11页
BACKGROUND Vaccines for coronavirus disease 2019(COVID-19) include Ch Ad Ox1-SARS-COV-2(Astra Zeneca),Ad26.COV2.S(Janssen),m RNA-1273(Moderna),BNT162b2(Pfizer),BBIBP-Cor V(Sinopharm),Corona Vac(Sinovac),and Bharat Bio... BACKGROUND Vaccines for coronavirus disease 2019(COVID-19) include Ch Ad Ox1-SARS-COV-2(Astra Zeneca),Ad26.COV2.S(Janssen),m RNA-1273(Moderna),BNT162b2(Pfizer),BBIBP-Cor V(Sinopharm),Corona Vac(Sinovac),and Bharat Biotech BBV152(Covaxin).AIM To find the association between COVID-19 vaccines and myocardial infarction(MI).METHODS This is a systematic review that involved searching databases such as MEDLINE,EMBASE,and Pak Medi Net after making a search strategy using Me SH and Emtree terms.Eligibility criteria were set,and studies having no mention of MI as a complication of COVID-19 vaccination,protocols,genetic studies,and animal studies were excluded.Data was extracted using a predesigned extraction table,and 29 studies were selected after screening and applying the eligibility criteria.RESULTS The majority of studies mentioned Astra Zeneca(18 studies) followed by Pfizer(14 studies) and Moderna(9 studies) in subjects reporting MI after vaccination.Out of all the studies,69% reported MI cases after the first COVID-19 vaccination dose and 14% after the second,44% reported ST-segment elevation MI,and 26% reported non-ST-segment elevation MI.The mortality rate was 29% after MI.CONCLUSION In conclusion,many studies linked MI to COVID-19 vaccinations,but no definitive association could be found. 展开更多
关键词 SARS-Co V-2 infection VACCINATION Myocardial infarction Association PFIZER Astra Zeneca Moderna Sinovac Janssen Covaxin
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部